Table 1.

Summary of immunological and challenge results

TreatmentMacaqueAnti-SIVsm H-4i neutralizing antibody titeraCTLs (lytic units)SIVsm E660 viremiad
SIV Gag specificbSIV Env specificcPeakPost-acute phase
SIV-VRPVW6121854379,210≤1,500
PE978595373,130≤1,500
WON25918141,899,00040,726
K2F≤201625943,50025,581
HA-VRPN2P≤20 NAe NA42,460,50044,339,026f
N8X≤20NANA6,539,000126,093
PBSN9K≤20NANA499,917,7001,281,454
W1A≤20NANA60,226,300102,877,164f
  • a On the day of challenge (Fig. 2B). The limit of detection was 20.

  • b Targets were infected with vaccinia virus expressing Gag-Pro-Pol (Fig. 3).

  • c Targets were infected with vaccinia virus expressing Env (Fig. 3).

  • d Genome equivalents per milliliter of plasma at peak viremia (2 or 3 weeks postchallenge) or geometric mean of two measurements taken during post-acute phase (6 to 8 weeks postchallenge [Fig. 4]). The limit of detection was 1,500.

  • e NA, not applicable. PBMCs from control animals could not be stimulated in vitro.

  • f Early mortality from SIV-induced disease.